Promoter sequences

ABSTRACT

The present invention relates an isolated human Site-1 Protease promoter region. The invention also relates to screening methods for agents decreasing the expression of Site-1 protease and thereby being potentially useful for the treatment of medical conditions related to obesity and/or diabetes.

TECHNICAL FIELD

[0001] The present invention relates an isolated human Site-1 Protease promoter region. The invention also relates to screening methods for agents decreasing the expression of Site-1 protease and thereby being potentially useful for the treatment of medical conditions related to obesity and/or diabetes.

BACKGROUND ART Sterol Regulatory Element-Binding Proteins (SREBPs)

[0002] The integrity of cell membranes is maintained by a balance between the amount of cholesterol and the amounts of unsaturated and saturated fatty acids in phospholipids. This balance is partly maintained by membrane-bound transcription factors called Sterol Regulatory Element-Binding Proteins (SREBPs; for reviews, see Brown & Goldstein (1997) Cell 89, 331-340; Brown & Goldstein (1999) Proc. Natl. Acad. Sci. U.S.A. 96, 11041-11048) that activate genes encoding enzymes of cholesterol and fatty acid biosynthesis. To enhance transcription, the active NH₂-terminal domains of SREBPs are released from endoplasmic reticulum membranes by two sequential cleavages. The first is catalyzed by Site-1 protease (SIP), a membrane-bound subtilisin-related serine protease that cleaves the hydrophilic loop of SREBP that projects into the endoplasmic reticulum lumen. The second cleavage, at Site-2, requires the action of S2P, a hydrophobic protein that appears to be a zinc metalloprotease. These regulated proteolytic cleavage reactions are ultimately responsible for controlling the level of cholesterol in membranes, cells, and blood.

[0003] Three isoforms of SREBPs have been identified. SREBP-1a and SREBP-1c are encoded by a single gene and differ in their N-terminal acid transcription activation domains. The N-terminus of SREBP-1a is longer and includes additional acidic amino acids, consistent with the observation that it is a more powerful transcription factor (Pai et al. (1998) Proc. Natl. Acad. Sci. U.S.A. 40, 26138-26148). SREBP-2 is produced by a different gene and contains a long activation domain resembling that of SREBP-1a. Recent evidence suggests that the main function of SREBP-2 is to regulate cholesterol synthesis whilst that of SREBP-1 is to regulate fatty acid synthesis (Pai et al., supra).

[0004] Inhibition of SREBP transcription factor function will lead to reduced cellular synthesis of free fatty acids and cholesterol, the clinical benefits of which are expected to include increased cellular insulin sensitivity and reduced coronary artery disease (CAD). Furthermore, SREBP-1 represents a cellular mechanism for increasing both fat cell size and number (Kim et al. (1998) J. Clin. Invest. 101, 1-9). Since most obesity generally involves an increase in both cell size and cell number, inhibition of SREBP-1 might be expected to have a positive effect on obesity. The hypolipidemic effects of dietary polyunsaturated fatty acids are believed to derive from a direct inhibitory effect on SREBP-1 expression (Xu et al. (1999) J. Biol. Chem. 274, 23577-23583).

[0005] There is data indicating independent regulation of SREBP-1 and SREBP-2 in hamster liver, suggesting the possibility for specific targeting of SREBP-1 or -2 (Sheng et al. (1995) Proc. Natl. Acad. Sci. U.S.A. 92, 935-938).

[0006] Transgenic mice over-expressing a dominant-positive form of SREBP-2 in the liver and adipose tissue showed greatly increased levels of mRNAs encoding multiple enzymes of cholesterol synthesis. Enzymes involved in fatty acid synthesis were also increased, however, to a lesser extent (Horton et al. (1998) J. Clin. Invest. 101, 2331-2339). Transgenic mice over-expressing a constitutively active SREBP-1a in the liver and adipose tissue showed greatly increased mRNA levels for enzymes involved in fatty acid and cholesterol (Shimano et al. (1996) J. Clin. Invest. 98, 1575-1584). Their livers were enlarged about 4-fold due to a massive accumulation of free fatty acids and cholesterol. Over-expression of a corresponding version of SREBP-1c in adipocytes of transgenic mice yielded insulin resistance and diabetes (Shimomura et al. (1999) Genes Dev. 12, 3182-3194). In cell culture such overexpression was previously shown to promote adipocyte differentiation. It has further been shown that overnutrition increases SREBP-1c expression in liver and islets of obese fa/fa Zucker diabetic fatty rats (Kakuma, T. et al. (2000) Proc. Natl. Acad. Sci. U.S.A. 97: 8536-8541).

S-1 Protease

[0007] As discussed above, SREBPs are activated by proteolysis, which releases the active transcription factor. The luminal subtilisin-like protease Site-1 Protease (S1P) is responsible for the first of the two proteolytic steps. Cleavage by S1P enables further cleavage by a Site-2 protease. S1P is the target for feedback inhibition by cholesterol.

[0008] S1P from hamster has been cloned (Sakai et al. (1998) Molecular Cell 2, 505-514). (GenBank accession no. AF078105; SEQ ID NOS: 5 and 6). The corresponding sequence of the (then unidentified) human gene was disclosed by Nagase et al. (1995) DNA Research 2, 37-43 (GenBank Accession no. D420453; SEQ ID NOS: 3 and 4)

[0009] SREBP and S1P are co-localized with a third protein: SREBP Cleavage-Activating Protein (SCAP), which is required for Site-1 cleavage in vivo. SCAP contains a site for sterol regulation, conserved in a small number of proteins, e.g. HMG-CoA reductase.

[0010] Only one S1P has been identified among the human expressed sequence tags (ESTs). Thus, S1P may be the only member of a subfamily among the subtilisin-like proteases.

[0011] Consequently, SREBPs are important regulators of fat and sugar metabolism in mammals and direct or indirect down-regulation of SREBPs may be of therapeutic value in type II diabetes; obesity, hypercholesterolemia, and other cardiovascular diseases or dyslipidemias.

[0012] Site-1 Protease represents a molecular target for therapeutic intervention which is expected to interfere with the SREBP pathway. Two principally distinct concepts for inhibition of the site-1-protease activity may be postulated; (i) by inactivation of the proteolytic activity (classical inhibitors) or (ii) by modulation of the site-1-protease gene expression level. In order to modulate the expression of the site-1-protease gene, there is a need for identification of regulatory regions responsible for the regulation of Site-1 protease promoter. Such regulatory regions in the promoter could be used for the identification of agents that inhibit expression of Site-1 protease, and thereby for the inhibition of the SREBP pathway.

DISCLOSURE OF THE INVENTION

[0013] The 5′-flanking region (promoter region) of the human Site-1 Protease (S1P) gene has been cloned and sequenced. This promoter region is useful in biological assays for the identification of compounds that inhibit the transcription of the Site-1 Protease. Inhibition of the SREBP pathway is expected to have therapeutic value in type II diabetes; obesity, hypercholesterolemia, and other cardiovascular diseases or dyslipidemias.

[0014] Consequently, in a first aspect this invention provides an isolated human site-1 protease promoter region comprising a sequence selected from:

[0015] (a) the nucleotide sequence set forth as SEQ I) NO: 2, or a fragment thereof exhibiting site-1 protease promoter activity;

[0016] (b) the complementary strand of (a); and

[0017] (c) nucleotide sequences capable of hybridizing, under stringent hybridization conditions, to a nucleotide sequence as defined in (a) or (b).

[0018] The term “promoter region” refers to a region of DNA that functions to control the transcription of one or more genes, and is structurally identified by the presence of a binding site for DNA-dependent RNA polymerase and of other DNA sequences on the same molecule which interact to regulate promoter function.

[0019] The nucleic acid molecules according to the present invention includes cDNA, chemically synthesized DNA, DNA isolated by PCR, genomic DNA, and combinations thereof. Genomic DNA may be obtained by screening a genomic library with the cDNA described herein, using methods that are well known in the art.

[0020] In a preferred form of the invention, the said nucleic acid molecule has a nucleotide sequence identical with SEQ ID NO: 2 of the Sequence Listing. However, the nucleic acid molecule according to the invention is not to be limited strictly to the sequence shown as SEQ ID NO: 2. Rather the invention encompasses nucleic acid molecules carrying modifications like substitutions, small deletions, insertions or inversions, which nevertheless have SIP promoter activity. Included in the invention are consequently nucleic acid molecules, the nucleotide sequence of which is at least 90% homologous, preferably at least 95% homologous, with the nucleotide sequence shown as SEQ ID NO: 2 in the Sequence Listing.

[0021] The term “stringent hybridization conditions” is known in the art from standard protocols (e.g. Ausubel et al., supra) and could be understood as e.g. hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at +65° C., and washing in 0.1×SSC /0.1% SDS at +68° C.

[0022] The said “fragment” (partial sequence) exhibiting site-1 protease promoter activity can be identified by the skilled person by computer-assisted sequence analysis, e.g. prediction of transcription factor binding sites.

[0023] The invention further provides a recombinant construct comprising the human site-1 protease promoter region as defined above. Preferably, the said construct comprises the S1P promoter region operably linked to a gene encoding a detectable product, in particular the human site-1 protease gene (SEQ ID NO: 3).

[0024] The term “linked” indicates that a nucleotide sequence encoding a gene product and an S1P promoter, or an active fragment thereof, are located within a continuous nucleic acid sequence. The term “operably linked” means that a nucleotide sequence, which can encode a gene product, is linked to the S1P promoter such that the S1P promoter regulates expression of the gene product under appropriate conditions. Two nucleotide sequences that are operably linked contain elements essential for transcription, including, for example, a TATA box.

[0025] The recombinant construct according to the invention could further comprise a reporter gene. As used herein, the term “reporter gene” means a gene encoding a gene product that can be identified using simple, inexpensive methods or reagents and that can be operably linked to a S1P promoter or an active fragment thereof. Reporter genes such as, for example, a luciferase, β-galactosidase, alkaline phosphatase, or green fluorescent protein reporter gene, can be used to determine transcriptional activity in screening assays according to the invention (see, for example, Goeddel (ed.), Methods Enzymol., Vol. 185, San Diego: Academic Press, Inc. (1990); see also Sambrook, supra).

[0026] In another aspect the invention provides a vector comprising the recombinant construct as defined above. The term “vector” refers to any carrier of exogenous DNA that is useful for transferring the DNA to a host cell for replication and/or appropriate expression of the exogenous DNA by the host cell. A host cell stably transformed with the recombinant construct is an additional aspect of the invention. Such a host cell can be a prokaryotic cell, a unicellular eukaryotic cell, or a cell derived from a multicellular organism. The methods employed to effect introduction of the vector into the host cell are standard methods well known to a person familiar with recombinant DNA methods. The term “transformed” or “transfected” refers to the process by which exogenous DNA is transferred into an appropriate host cell.

[0027] In a further important aspect, this invention is useful in screening for pharmacological agents that modulate S1P levels by affecting the transcription of the S1P gene. As used herein, the term “agent” means a biological or chemical compound such as a simple or complex organic molecule, a peptide, a protein or an oligonucleotide. Consequently, this invention includes a method for identifying an agent capable of modulating the S1P promoter, comprising providing a cell comprising the S1P promoter; contacting said cell with a candidate agent; and monitoring said cell for an effect that is not present in the absence of said candidate agent.

[0028] A preferred form of the invention include a method for identification of an agent capable of decreasing or inhibiting site-1 protease promoter activity, said method comprising the steps (i) contacting a candidate agent with the human site-1 protease promoter; and (ii) determining whether said candidate agent decreases expression of the site-1 protease gene, such decrease being indicative for an agent capable of decreasing or inhibiting site-1 protease promoter activity.

[0029] For screening purposes, appropriate host cells can be transformed with a vector having a reporter gene under the control of the human S1P promoter according to this invention. The expression of the reporter gene can be measured in the presence or absence of an agent with known activity (i.e. a standard agent) or putative activity (i.e. a “test agent” or “candidate agent”). A change in the level of expression of the reporter gene in the presence of the test agent is compared with that effected by the standard agent. In this way, active agents are identified and their relative potency in this assay determined.

[0030] It will be understood that agents acting on the human S1P promoter can be identified by, as an additional step, analyzing direct binding interactions between the candidate agent and the human S1P promoter. Interactions with large molecules may be studied using techniques such as gel shift analysis, footprinting or NMR (see Latchman, D. S. (Ed.) (1995) Methods for studying transcription factors. In: Eukaryotic transcription factors. Academic Press, London, pp. 17-44). Small molecule compounds which appear to bind reversibly to double stranded DNA without intercalation between DNA base pairs have been defined. Methods are described by which this non-intercalative binding can be characterized using ultraviolet spectrometry, fluorimetry with ethidium as a probe, viscometry and other hydrodynamic techniques, circular dichroism and nuclear magnetic resonance spectrometry (See Baguley, B. C. (1982) Nonintercalative DNA-binding antitumour compounds. Mol Cell Biochem 43: 167-181; Gmeiner, W. H. (1998) NMR spectroscopy as a tool to investigate the structural basis of anticancer drugs. Curr Med Chem 5(2):115-135; Wemmer, D. E. & Williams, P. G. (1994) Use of nuclear magnetic resonance in probing ligand-macromolecule interactions. Methods Enzymol. 239:739-767)

[0031] A potentially useful method for identification of agents acting on the human S1P promoter is described in Swedish patent application No. 0101218-6, filed on Apr. 5, 2001. Such a method comprises the steps

[0032] (a) predicting the structure of an RNA-fragment;

[0033] (b) choosing a suitable predicted RNA-fragment of step (a), which RNA-fragment comprises at least one individual stem;

[0034] (c) synthesizing the DNA-fragment corresponding to the RNA-fragment of step (b);

[0035] (d) inserting the DNA-fragment of step (c) in the upstream proximity of a reporter assay gene, which reporter assay gene produces a signal upon translation, thereby forming a reporter construct;

[0036] (e) performing a reporter gene assay, which assay monitors the interaction between a molecule to be tested for RNA-binding and the RNA-fragment of the reporter construct.

[0037] As mentioned above, it is expected that agents capable of decreasing or inhibiting site-1 protease promoter activity have potential therapeutic value in particular in obesity, and in type II diabetes; hypercholesterolemia, atherosclerosis and other cardiovascular diseases or dyslipidemias. Consequently, the invention comprises a method for the treatment of medical conditions related to obesity, comprising administering to a patient in need thereof a therapeutically effective amount of an agent identified by the method according to the invention.

[0038] The term “treatment” means any treatment of a diseases in a mammal, including: (i) preventing the disease, i.e. causing the clinical symptoms of the disease not to develop; (ii) inhibiting the disease, i.e. arresting the development of clinical symptoms; and/or (iii) relieving the disease, i.e. causing the regression of clinical symptoms. The term “effective amount” means a dosage sufficient to provide treatment for the disease state being treated. This will vary depending on the patient, the disease and the treatment being effected.

[0039] Throughout this description the terms “standard protocols” and “standard procedures”, when used in the context of molecular biology techniques, are to be understood as protocols and procedures found in an ordinary laboratory manual such as: Current Protocols in Molecular Biology, editors F. Ausubel et al., John Wiley and Sons, Inc. 1994, or Sambrook, J., Fritsch, E. F. and Maniatis, T., Molecular Cloning: A laboratory manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. 1989.

EXAMPLES Example 1 Cloning of S1P Promoter Fragment

[0040] For cloning of the 5′-flanking region of the S1-protease gene, a genomic walking strategy was used, principally as described by Siebert et al. (1995) Nucleic Acids Res. 23,1087-1088; and Siebert et al. (1995) CLONTECHniques X, 1-3. Two primers, designated FOMA 345 and FOMA 346, were selected in the 5′-region of the cDNA:

[0041] FOMA 345: 5′-CTC CGC GGC GAA CAC GCCT-3′ (corresponding to positions 126-108 in SEQ ID NO: 3);

[0042] FOMA 346: 5′-CGG GAG CTC AGG GCC GGC-3′ (corresponding to positions 163-146 in SEQ ID NO: 3).

[0043] All other reagents used were obtained with a “Genome Walker Kit” (Clontech, Palo Alto, Calif.). The principle of this procedure is to perform two subsequent PCR reactions using adaptor-ligated genomic DNA as template. In the first PCR reaction the “outer” primers are used, i.e. FOMA 345 and AP1 (adaptor primer 1). The protocol for this reaction was:

[0044] (+95° for 25 sec; +72° for 4 min)×7 cycles (+95° for 25 sec; +67° for 4 min)×35 cycles (+670 for 4 min)×1 cycle

[0045] In the second PCR reaction, the “inner” primers were used (FOMA 346 and AP2). The reaction mix from the first PCR was diluted 50 times and 1 μl of this cocktail was used as template in the second reaction. The protocol of the second reaction was:

[0046] (+950 for 25 sec; +72° for 4 min)×5 cycles

[0047] (+950 for 25 sec; +67° for 4 min)×25 cycles

[0048] (+670 for 4 min)×1 cycle

[0049] The reaction mixes were prepared in accordance with the instructions of the kit manufacturer. After the second PCR, the product was analyzed by electrophoresis in 2% agarose gel. A product, approximately 1 kb long, was observed in one of the adaptor-ligated genomic DNA-libraries (HDL2). This product was cloned into the TOPO vector PCR2.1 (Invitrogen, Carlsbad, Calif.) by standard cloning procedures and thereafter sequenced. A 980 bp sequence was obtained (SEQ ID NO: 1).

Example 2 Assembly of S1P Promoter Sequence

[0050] The Celera database (Release 1.13) was searched using the 980 bp sequence obtained in Example 1 as query sequence. The BLAST algorithm (Altschul et al. (1997) Nucleic Acids Res. 25:3389-3402) was used for determining sequence identity. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/). Six fragments (GA_(—)16330554; GA_(—)25791426; GA_(—)23194195; GA_(—)28969362; GA_(—)18902492; GA_(—)24454650) that overlapped with the genomic sequence were retrieved. These six fragments were used to search the Celera database (Release 1.13) again, the overlapping sequences were extended with another 7 fragments (GA_(—)24421404, GA_(—)21984802, GA_(—)28735370, GA_(—)21045430, GA_(—)9491232, GA_(—)13453697, GA_(—)25224137). All 13 fragments together with the 980 bp sequence obtained in Example 1 were finally assembled to a 2469 bp contig (SEQ ID NO: 2) using the Cap2 program (Huang (1996) Genomics 33, 21-31).

Example 3 Reporter Gene Assay to Identify Modulating Compounds

[0051] Reporter gene assays are well known as tools to signal transcriptional activity in cells. (For a review of chemiluminescent and bioluminescent reporter gene assays, see Bronstein et al. (1994) Analytical Biochemistry 219, 169-181.) For instance, the photoprotein luciferase provides a useful tool for assaying for modulators of S 1P promoter activity. Cells (e.g. CHO cells or COS 7 cells) are transiently co-transfected with both a Site-1 protease expression construct and a reporter construct which includes a gene for the luciferase protein downstream from a transcription factor binding site. Luciferase activity may be quantitatively measured using e.g. luciferase assay reagents that are commercially available from Promega (Madison, Wis.). Differences in luminescence in the presence versus the absence of a candidate modulator compound are indicative of modulatory activity.

[0052] A luciferase reporter plasmid is prepared by cloning a 980 bp sequence (SEQ ID NO: 1) corresponding to a part of the site-1 -protease promoter into the pGL2 vector, in which the luciferase reporter gene is driven by the activity of the inserted promoter. The construct is thereafter transfected into the mouse pre-adipocyte cell line 3T3-L1 (ATCC No. CCL92.1), the human embryonic kidney cell line 293 (ATCC No. CRL-1573), and the human hepatoma cell line HepG2 (ATCC No. HB-8065). Altered promoter activity after stimulation with a number of substances, including insulin, glitazones and sterols, are measured as changes in the readout of luciferase.

1 6 1 980 DNA Homo sapiens 1 ctccgcggcg aacacgcctg ggcactccat tcggggctgt ttactcccaa ctctcgcgag 60 actgggcggc cgggccagcg aggcccacag ctgggagcct cagctccgcc gacccagcgt 120 gccctgtctg tcccgcgctc ccggggcttg cgtgcgcgct ctggacgccg tgggcagcgg 180 gaccacgccg ggaggatgga cgaaggtgct cgcgacattt gcggcggcgg gggccggtgg 240 cagggtggaa gcggaggggc gtggccagcg agctgccagg cggcgagaac gcgctggggg 300 aacccttggt ccgctctgcg cgtcgctcta ggatccccga aaaggagcac gggcgcgaaa 360 gcggccaggc tgggccagga tctagaaaga ctgcctggcg caggctccct gcccccgcgg 420 gcctgctgtc atggactcgt ggagagctcg cttcccgcgc ggacccttcc tgcaggggtc 480 cacgtccagg caccggcggc tcggacaccc cacccccggc cgggcacctg ccctgggtgc 540 cccttaaccc gggcggtagc tcgttaagat ggcgaagtgt ccggtccgga acacgcgaaa 600 ccccaaatcc cgcctgcccg acctcctgac ccccggcccc acgggacgac agactgggcc 660 tcccgacgcg cagcgcgctg ccgggacacc ggtgcgtgcg aaacggagga cctttgtaac 720 gccacgtgtt tgctcttttt gaaaaaacaa gaataaatgt gttaaactgt ctgaaaagct 780 tgccgcctaa aagatgtctg ggtgacttag atgctaggat cagtttgttt tcaatgtaaa 840 tggaccagcc cggactccgt acggcactag caggggactg aaagcgtctt caggtactgc 900 tggtgggcgg tgatgcgcta caggccgatc agacagtttt gtgtcttctg gaacttgaca 960 ctgcaccacg gtaatgctga 980 2 2469 DNA Homo sapiens 2 ttgagtctgt ctggaggctc cgggccagag cagggcgtat tgtttcactc ggtgaatgct 60 catttcacgt aaagaaaacc aggcaacgga acaagctgcc ggagcgcgca gacccccgca 120 gggccgcggt acaggcacgc tgtgtccaaa caagcgccgg aggccccgcg cccacctccc 180 ccgacccggc ccggcccccg cagccctcgc ctcggggcct cggacgcaac cggcacacct 240 gagcgagcgg gccgccaccg ctaggcggag cgggtcgggg aggccgcgcg cgggcggctg 300 acgtacctgc gccgccggga gctcagggcc ggcgggcccg ggatgacggc gcctccgcgg 360 cgaacacgcc tgggcactcc attcggggct gtttactccc aactctcgcg agactgggcg 420 gccgggccag cgaggcccac agctgggagc ctcagctccg ccgacccagc gtgccctgtc 480 tgtcccgcgc tcccggggct tgcgtgcgcg ctctggacgc cgtgggcagc gggaccacgc 540 cgggaggatg gacgaaggtg ctcgcgacat ttgcggcggc gggggccggt ggcagggtgg 600 aagcggaggg gcgtggccag cgagctgcca ggcggcgaga acgcgctggg ggaacccttg 660 gtccgctctg cgcgtcgctc taggatcccc gaaaaggagc acgggcgcga aagcggccag 720 gctgggccag gatctagaaa gactgcctgg cgcaggctcc ctgcccccgc gggcctgctg 780 tcatggactc gtggagagct cgcttcccgc gcggaccctt cctgcagggg tccacgtcca 840 ggcaccggcg gctcggacac cccacccccg gccgggcacc tgccctgggt gccccttaac 900 ccgggcggta gctcgttaag atggcgaagt gtccggtccg gaacacgcga aaccccaaat 960 cccgcctgcc cgacctcctg acccccggcc ccacgggacg acagactggg cctcccgacg 1020 cgcagcgcgc tgccgggaca ccggtgcgtg cgaaacggag gacctttgta acgccacgtg 1080 tttgctcttt ttgaaaaaac aagaataaat gtgttaaact gtctgaaaag cttgccgcct 1140 aaaagatgtc tgggtgactt agatgctagg atcagtttgt tttcaatgta aatggaccag 1200 cccggactcc gtacggcact agcaggggac tgaaagcgtc ttcaggtact gctggtgggc 1260 ggtgatgcgc tacaggccga tcagacagtt ttgtgtcttc tggaacttga cactgcacca 1320 cggtaatgct gaactgcacc aatattacag atcacagcgc atcatcttcc ttcaacatga 1380 tttaacacag ttgacttaat atggtggata aatgtagaat cacaaattac cataccccac 1440 ctcaggcttc tacttcgtaa ttttgagcag gttgtttaac ctctttgtac ctcagcttct 1500 tcattacaaa aataggggta ctagccaggc ggggtggctc gcgcctgtaa tcccagcact 1560 tggggaggcc gaggcagccg gatcacttga ggtcagaagt ttcagaccag cctggtcaac 1620 atgggtgaaa cgccggctct accaaaaata taaaaactta gctgagtgtg gtagcgcatg 1680 actgtaatcc cagcaactca ggaggctgag gcagagaatc gcttgaacct gggaggcgga 1740 ggttgcagtg agctgagatc gtaccactgc actccagctt gggcgacaga gcgagactct 1800 gccttaaaaa taaataaata atttttaaaa aaaatagggg tactaatatc taccttaaag 1860 gatgagggtt aaattaagta cacacataag ccctagcgca gtggcttatg cctgtaatct 1920 caacactttg ggagtctgtg gcgggaggat cacttgagcc caggagtttg agactagtct 1980 gggcaacaga gacatgtctc tatagttgtg tttggttttg tttttaccag gtgtggtggt 2040 gtgcacctgc agtcccagct actagggagg ctgaggtggg aggactgcct gagcccagga 2100 ggtcgaggct gcagtgagcc atgattgtgc cactgcactc cagcctgggc aacacagcaa 2160 gaccttgtct caaaaacaaa caaaaagcat actcataaag tgctcggctc ctatatgatt 2220 caatatgtgg tggtggattc ttgaatcctt tcctgactca gatctcatac gattttctga 2280 acttttggag aatccttgcc tctctgcatt tgcaaaccgt caaaggcact cccttctgcc 2340 accacacaaa gcatttgatt ttaaacttga ctatgtcctt ctgttccaac tttaggtaaa 2400 ttaatcttgg tcagggttct ctgaacagcc ctttagtcac tatgccattg aatacatggc 2460 cctacagct 2469 3 4338 DNA Homo sapiens CDS (497)..(3655) 3 cagggcacgc tgggtcggcg gagctgaggc tcccagctgt gggcctcgct ggcccggtcg 60 cccagtctcg cgagagttgg gagtaaacag ccccgaatgg agtgcccagg cgtgttcgcc 120 gcggaggcgc cgttatcccg ggcccgccgg ccctgagctc ccggcggcgc agattggctc 180 acagtggttg attgatcaac cccattggac gttggttctg tggtacaaat ggagtacagg 240 actcagtcgt cacggcctga gtgagagaag ccttatttcc aagatggaga agaagcggag 300 aaagaaatga aagcctctct tcaggctgaa ccacaaaagg ccatgggatt taacttttat 360 ttatgttggg caagactgta agatggctga tcagtaatgt tgcagctttt agctgaaaca 420 aaaattcact tttaatcaag aagaaaaaag tgtgatttga atatatgcaa ttttatgatc 480 atattcgctt gtgacc atg aag ctt gtc aac atc tgg ctg ctt ctg ctc gtg 532 Met Lys Leu Val Asn Ile Trp Leu Leu Leu Leu Val 1 5 10 gtt ttg ctc tgt ggg aag aaa cat ctg ggc gac aga ctg gaa aag aaa 580 Val Leu Leu Cys Gly Lys Lys His Leu Gly Asp Arg Leu Glu Lys Lys 15 20 25 tct ttt gaa aag gcc cca tgc cct ggc tgt tcc cac ctg act ttg aag 628 Ser Phe Glu Lys Ala Pro Cys Pro Gly Cys Ser His Leu Thr Leu Lys 30 35 40 gtg gaa ttc tca tca aca gtt gtg gaa tat gaa tat att gtg gct ttc 676 Val Glu Phe Ser Ser Thr Val Val Glu Tyr Glu Tyr Ile Val Ala Phe 45 50 55 60 aat gga tac ttt aca gcc aaa gct aga aat tca ttt att tca agt gcc 724 Asn Gly Tyr Phe Thr Ala Lys Ala Arg Asn Ser Phe Ile Ser Ser Ala 65 70 75 ctg aag agc agt gaa gta gac aat tgg aga att ata cct cga aac aat 772 Leu Lys Ser Ser Glu Val Asp Asn Trp Arg Ile Ile Pro Arg Asn Asn 80 85 90 cca tcc agt gac tac cct agt gat ttt gag gtg att cag ata aaa gaa 820 Pro Ser Ser Asp Tyr Pro Ser Asp Phe Glu Val Ile Gln Ile Lys Glu 95 100 105 aaa cag aaa gcg ggg ctg cta aca ctt gaa gat cat cca aac atc aaa 868 Lys Gln Lys Ala Gly Leu Leu Thr Leu Glu Asp His Pro Asn Ile Lys 110 115 120 cgg gtc acg ccc caa cga aaa gtc ttt cgt tcc ctc aag tat gct gaa 916 Arg Val Thr Pro Gln Arg Lys Val Phe Arg Ser Leu Lys Tyr Ala Glu 125 130 135 140 tct gac ccc aca gta ccc tgc aat gaa acc cgg tgg agc cag aag tgg 964 Ser Asp Pro Thr Val Pro Cys Asn Glu Thr Arg Trp Ser Gln Lys Trp 145 150 155 caa tca tca cgt ccc ctg cga aga gcc agc ctc tcc ctg ggc tct ggc 1012 Gln Ser Ser Arg Pro Leu Arg Arg Ala Ser Leu Ser Leu Gly Ser Gly 160 165 170 ttc tgg cat gct acg gga agg cat tcg agc aga cgg ctg ctg aga gcc 1060 Phe Trp His Ala Thr Gly Arg His Ser Ser Arg Arg Leu Leu Arg Ala 175 180 185 atc ccg cgc cag gtt gcc cag aca ctg cag gca gat gtg ctc tgg cag 1108 Ile Pro Arg Gln Val Ala Gln Thr Leu Gln Ala Asp Val Leu Trp Gln 190 195 200 atg gga tat aca ggt gct aat gta aga gtt gct gtt ttt gac act ggg 1156 Met Gly Tyr Thr Gly Ala Asn Val Arg Val Ala Val Phe Asp Thr Gly 205 210 215 220 ctg agc gag aag cat ccc cac ttc aaa aat gtg aag gag aga acc aac 1204 Leu Ser Glu Lys His Pro His Phe Lys Asn Val Lys Glu Arg Thr Asn 225 230 235 tgg acc aac gag cga acg ctg gac gat ggg ttg ggc cat ggc aca ttc 1252 Trp Thr Asn Glu Arg Thr Leu Asp Asp Gly Leu Gly His Gly Thr Phe 240 245 250 gtg gca ggt gtg ata gcc agc atg agg gag tgc caa gga ttt gct cca 1300 Val Ala Gly Val Ile Ala Ser Met Arg Glu Cys Gln Gly Phe Ala Pro 255 260 265 gat gca gaa ctt cac att ttc agg gtc ttt acc aat aat cag gta tct 1348 Asp Ala Glu Leu His Ile Phe Arg Val Phe Thr Asn Asn Gln Val Ser 270 275 280 tac aca tct tgg ttt ttg gac gcc ttc aac tat gcc att tta aag aag 1396 Tyr Thr Ser Trp Phe Leu Asp Ala Phe Asn Tyr Ala Ile Leu Lys Lys 285 290 295 300 atc gac gtg tta aac ctc agc atc ggc ggc ccg gac ttc atg gat cat 1444 Ile Asp Val Leu Asn Leu Ser Ile Gly Gly Pro Asp Phe Met Asp His 305 310 315 ccg ttt gtt gac aag gtg tgg gaa tta aca gct aac aat gta atc atg 1492 Pro Phe Val Asp Lys Val Trp Glu Leu Thr Ala Asn Asn Val Ile Met 320 325 330 gtt tct gct att ggc aat gac gga cct ctt tat ggc act ctg aat aac 1540 Val Ser Ala Ile Gly Asn Asp Gly Pro Leu Tyr Gly Thr Leu Asn Asn 335 340 345 cct gct gat caa atg gat gtg att gga gta ggc ggc att gac ttt gaa 1588 Pro Ala Asp Gln Met Asp Val Ile Gly Val Gly Gly Ile Asp Phe Glu 350 355 360 gat aac atc gcc cgc ttt tct tca agg gga atg act acc tgg gag cta 1636 Asp Asn Ile Ala Arg Phe Ser Ser Arg Gly Met Thr Thr Trp Glu Leu 365 370 375 380 cca gga ggc tac ggt cgc atg aaa cct gac att gtc acc tat ggt gct 1684 Pro Gly Gly Tyr Gly Arg Met Lys Pro Asp Ile Val Thr Tyr Gly Ala 385 390 395 ggc gtg cgg ggt tct ggc gtg aaa ggg ggg tgc cgg gcc ctc tca ggg 1732 Gly Val Arg Gly Ser Gly Val Lys Gly Gly Cys Arg Ala Leu Ser Gly 400 405 410 acc agt gtt gct tct cca gtg gtt gca ggt gct gtc acc ttg tta gtg 1780 Thr Ser Val Ala Ser Pro Val Val Ala Gly Ala Val Thr Leu Leu Val 415 420 425 agc aca gtc cag aag cgt gag ctg gtg aat ccc gcc agt atg aag cag 1828 Ser Thr Val Gln Lys Arg Glu Leu Val Asn Pro Ala Ser Met Lys Gln 430 435 440 gcc ctg atc gcg tca gcc cgg agg ctc ccc ggg gtc aac atg ttt gag 1876 Ala Leu Ile Ala Ser Ala Arg Arg Leu Pro Gly Val Asn Met Phe Glu 445 450 455 460 caa ggc cac ggc aag ctc gat ctg ctc aga gcc tat cag atc ctc aac 1924 Gln Gly His Gly Lys Leu Asp Leu Leu Arg Ala Tyr Gln Ile Leu Asn 465 470 475 agc tac aag cca cag gca agt ttg agc ccc agc tac ata gat ctg act 1972 Ser Tyr Lys Pro Gln Ala Ser Leu Ser Pro Ser Tyr Ile Asp Leu Thr 480 485 490 gag tgt ccc tac atg tgg ccc tac tgc tcc cag ccc atc tac tat gga 2020 Glu Cys Pro Tyr Met Trp Pro Tyr Cys Ser Gln Pro Ile Tyr Tyr Gly 495 500 505 gga atg ccg aca gtt gtt aat gtc acc atc ctc aac ggc atg gga gtc 2068 Gly Met Pro Thr Val Val Asn Val Thr Ile Leu Asn Gly Met Gly Val 510 515 520 aca gga aga att gta gat aag cct gac tgg cag ccc tat ttg cca cag 2116 Thr Gly Arg Ile Val Asp Lys Pro Asp Trp Gln Pro Tyr Leu Pro Gln 525 530 535 540 aac gga gac aac att gaa gtt gcc ttc tcc tac tcc tcg gtc tta tgg 2164 Asn Gly Asp Asn Ile Glu Val Ala Phe Ser Tyr Ser Ser Val Leu Trp 545 550 555 cct tgg tcg ggc tac ctg gcc atc tcc att tct gtg acc aag aaa gcg 2212 Pro Trp Ser Gly Tyr Leu Ala Ile Ser Ile Ser Val Thr Lys Lys Ala 560 565 570 gct tcc tgg gaa ggc att gct cag ggc cat gtc atg atc act gtg gct 2260 Ala Ser Trp Glu Gly Ile Ala Gln Gly His Val Met Ile Thr Val Ala 575 580 585 tcc cca gca gag aca gag tca aaa aat ggt gca gaa cag act tca aca 2308 Ser Pro Ala Glu Thr Glu Ser Lys Asn Gly Ala Glu Gln Thr Ser Thr 590 595 600 gta aag ctc ccc att aag gtg aag ata att cct act ccc ccg cga agc 2356 Val Lys Leu Pro Ile Lys Val Lys Ile Ile Pro Thr Pro Pro Arg Ser 605 610 615 620 aag aga gtt ctc tgg gat cag tac cac aac ctc cgc tat cca cct ggc 2404 Lys Arg Val Leu Trp Asp Gln Tyr His Asn Leu Arg Tyr Pro Pro Gly 625 630 635 tat ttc ccc agg gat aat tta agg atg aag aat gac cct tta gac tgg 2452 Tyr Phe Pro Arg Asp Asn Leu Arg Met Lys Asn Asp Pro Leu Asp Trp 640 645 650 aat ggt gat cac atc cac acc aat ttc agg gat atg tac cag cat ctg 2500 Asn Gly Asp His Ile His Thr Asn Phe Arg Asp Met Tyr Gln His Leu 655 660 665 aga agc atg ggc tac ttt gta gag gtc ctc ggg gcc ccc ttc acg tgt 2548 Arg Ser Met Gly Tyr Phe Val Glu Val Leu Gly Ala Pro Phe Thr Cys 670 675 680 ttt gat gcc agt cag tat ggc act ttg ctg atg gtg gac agt gag gag 2596 Phe Asp Ala Ser Gln Tyr Gly Thr Leu Leu Met Val Asp Ser Glu Glu 685 690 695 700 gag tac ttc cct gaa gag atc gcc aag ctc cgg agg gac gtg gac aac 2644 Glu Tyr Phe Pro Glu Glu Ile Ala Lys Leu Arg Arg Asp Val Asp Asn 705 710 715 ggc ctc tcg ctc gtc atc ttc agt gac tgg tac aac act tct gtt atg 2692 Gly Leu Ser Leu Val Ile Phe Ser Asp Trp Tyr Asn Thr Ser Val Met 720 725 730 aga aaa gtg aag ttt tat gat gaa aac aca agg cag tgg tgg atg ccg 2740 Arg Lys Val Lys Phe Tyr Asp Glu Asn Thr Arg Gln Trp Trp Met Pro 735 740 745 gat acc gga gga gct aac atc cca gct ctg aat gag ctg ctg tct gtg 2788 Asp Thr Gly Gly Ala Asn Ile Pro Ala Leu Asn Glu Leu Leu Ser Val 750 755 760 tgg aac atg ggg ttc agc gat ggc ctg tat gaa ggg gag ttc acc ctg 2836 Trp Asn Met Gly Phe Ser Asp Gly Leu Tyr Glu Gly Glu Phe Thr Leu 765 770 775 780 gcc aac cat gac atg tat tat gcg tca ggg tgc agc atc gcg aag ttt 2884 Ala Asn His Asp Met Tyr Tyr Ala Ser Gly Cys Ser Ile Ala Lys Phe 785 790 795 cca gaa gat ggc gtc gtg ata aca cag act ttc aag gac caa gga ttg 2932 Pro Glu Asp Gly Val Val Ile Thr Gln Thr Phe Lys Asp Gln Gly Leu 800 805 810 gag gtt tta aag cag gaa aca gca gtt gtt gaa aac gtc ccc att ttg 2980 Glu Val Leu Lys Gln Glu Thr Ala Val Val Glu Asn Val Pro Ile Leu 815 820 825 gga ctt tat cag att cca gct gag ggt gga ggc cgg att gta ctg tat 3028 Gly Leu Tyr Gln Ile Pro Ala Glu Gly Gly Gly Arg Ile Val Leu Tyr 830 835 840 ggg gac tcc aat tgc ttg gat gac agt cac cga cag aag gac tgc ttt 3076 Gly Asp Ser Asn Cys Leu Asp Asp Ser His Arg Gln Lys Asp Cys Phe 845 850 855 860 tgg ctt ctg gat gcc ctc ctc cag tac aca tcg tat ggg gtg aca ccg 3124 Trp Leu Leu Asp Ala Leu Leu Gln Tyr Thr Ser Tyr Gly Val Thr Pro 865 870 875 cct agc ctc agt cac tct ggg aac cgc cag cgc cct ccc agt gga gca 3172 Pro Ser Leu Ser His Ser Gly Asn Arg Gln Arg Pro Pro Ser Gly Ala 880 885 890 ggc tca gtc act cca gag agg atg gaa gga aac cat ctt cat cgg tac 3220 Gly Ser Val Thr Pro Glu Arg Met Glu Gly Asn His Leu His Arg Tyr 895 900 905 tcc aag gtt ctg gag gcc cat ttg gga gac cca aaa cct cgg cct cta 3268 Ser Lys Val Leu Glu Ala His Leu Gly Asp Pro Lys Pro Arg Pro Leu 910 915 920 cca gcc tgt cca cgc ttg tct tgg gcc aag cca cag cct tta aac gag 3316 Pro Ala Cys Pro Arg Leu Ser Trp Ala Lys Pro Gln Pro Leu Asn Glu 925 930 935 940 acg gcg ccc agt aac ctt tgg aaa cat cag aag cta ctc tcc att gac 3364 Thr Ala Pro Ser Asn Leu Trp Lys His Gln Lys Leu Leu Ser Ile Asp 945 950 955 ctg gac aag gtg gtg tta ccc aac ttt cga tcg aat cgc cct caa gtg 3412 Leu Asp Lys Val Val Leu Pro Asn Phe Arg Ser Asn Arg Pro Gln Val 960 965 970 agg ccc ttg tcc cct gga gag agc ggc gcc tgg gac att cct gga ggg 3460 Arg Pro Leu Ser Pro Gly Glu Ser Gly Ala Trp Asp Ile Pro Gly Gly 975 980 985 atc atg cct ggc cgc tac aac cag gag gtg ggc cag acc att cct gtc 3508 Ile Met Pro Gly Arg Tyr Asn Gln Glu Val Gly Gln Thr Ile Pro Val 990 995 1000 ttt gcc ttc ctg gga gcc atg gtg gtc ctg gcc ttc ttt gtg gta caa 3556 Phe Ala Phe Leu Gly Ala Met Val Val Leu Ala Phe Phe Val Val Gln 1005 1010 1015 1020 atc aac aag gcc aag agc agg ccg aag cgg agg aag ccc agg gtg aag 3604 Ile Asn Lys Ala Lys Ser Arg Pro Lys Arg Arg Lys Pro Arg Val Lys 1025 1030 1035 cgc ccg cag ctc atg cag cag gtt cac ccg cca aag acc cct tcg gtg 3652 Arg Pro Gln Leu Met Gln Gln Val His Pro Pro Lys Thr Pro Ser Val 1040 1045 1050 tga ccggcagcct ggctgaccgt gagggccaga gagagccttc acggacggcg 3705 ctggtgggtg agccgagctg tggtggcggc tggtttaaaa gggatccagt ttccagctgc 3765 aggtttgtta gagtctgttc tacatgggcc tgccctcctg tgatgggcag aggctcctgg 3825 tacatcgaga agattcctgt ggatcccgtc aggagggact tagtggctct gccgccagtg 3885 agacttcccg ccggcagctg tgcgcaccaa agactcggga gaactggaaa ggctgtctgg 3945 ggtcttctga ctgcagggga aggatgtact ttccaaacaa atgatacaac cctgaccaag 4005 ctaaaagacg cttgttaaag gctattttct atatttattg ttgggaaaag tcactttaaa 4065 gacttgtgct atttggaagc aaagctattt tttttgtcag tggaatgcag tttttttact 4125 attccatcat gaggaacaac atagattcca tgatcttttt aatgacagta cagactgaga 4185 tttgaaggaa acatgcacaa atctgtaaaa catagacctt cgctttattt ttgtaagtat 4245 cacctgccac catgttttgt aatttgaggt cttgatttca ccattgtcgg tgaagaaaat 4305 tttcaataaa tatgtattac ccgtctgaag ctt 4338 4 1052 PRT Homo sapiens 4 Met Lys Leu Val Asn Ile Trp Leu Leu Leu Leu Val Val Leu Leu Cys 1 5 10 15 Gly Lys Lys His Leu Gly Asp Arg Leu Glu Lys Lys Ser Phe Glu Lys 20 25 30 Ala Pro Cys Pro Gly Cys Ser His Leu Thr Leu Lys Val Glu Phe Ser 35 40 45 Ser Thr Val Val Glu Tyr Glu Tyr Ile Val Ala Phe Asn Gly Tyr Phe 50 55 60 Thr Ala Lys Ala Arg Asn Ser Phe Ile Ser Ser Ala Leu Lys Ser Ser 65 70 75 80 Glu Val Asp Asn Trp Arg Ile Ile Pro Arg Asn Asn Pro Ser Ser Asp 85 90 95 Tyr Pro Ser Asp Phe Glu Val Ile Gln Ile Lys Glu Lys Gln Lys Ala 100 105 110 Gly Leu Leu Thr Leu Glu Asp His Pro Asn Ile Lys Arg Val Thr Pro 115 120 125 Gln Arg Lys Val Phe Arg Ser Leu Lys Tyr Ala Glu Ser Asp Pro Thr 130 135 140 Val Pro Cys Asn Glu Thr Arg Trp Ser Gln Lys Trp Gln Ser Ser Arg 145 150 155 160 Pro Leu Arg Arg Ala Ser Leu Ser Leu Gly Ser Gly Phe Trp His Ala 165 170 175 Thr Gly Arg His Ser Ser Arg Arg Leu Leu Arg Ala Ile Pro Arg Gln 180 185 190 Val Ala Gln Thr Leu Gln Ala Asp Val Leu Trp Gln Met Gly Tyr Thr 195 200 205 Gly Ala Asn Val Arg Val Ala Val Phe Asp Thr Gly Leu Ser Glu Lys 210 215 220 His Pro His Phe Lys Asn Val Lys Glu Arg Thr Asn Trp Thr Asn Glu 225 230 235 240 Arg Thr Leu Asp Asp Gly Leu Gly His Gly Thr Phe Val Ala Gly Val 245 250 255 Ile Ala Ser Met Arg Glu Cys Gln Gly Phe Ala Pro Asp Ala Glu Leu 260 265 270 His Ile Phe Arg Val Phe Thr Asn Asn Gln Val Ser Tyr Thr Ser Trp 275 280 285 Phe Leu Asp Ala Phe Asn Tyr Ala Ile Leu Lys Lys Ile Asp Val Leu 290 295 300 Asn Leu Ser Ile Gly Gly Pro Asp Phe Met Asp His Pro Phe Val Asp 305 310 315 320 Lys Val Trp Glu Leu Thr Ala Asn Asn Val Ile Met Val Ser Ala Ile 325 330 335 Gly Asn Asp Gly Pro Leu Tyr Gly Thr Leu Asn Asn Pro Ala Asp Gln 340 345 350 Met Asp Val Ile Gly Val Gly Gly Ile Asp Phe Glu Asp Asn Ile Ala 355 360 365 Arg Phe Ser Ser Arg Gly Met Thr Thr Trp Glu Leu Pro Gly Gly Tyr 370 375 380 Gly Arg Met Lys Pro Asp Ile Val Thr Tyr Gly Ala Gly Val Arg Gly 385 390 395 400 Ser Gly Val Lys Gly Gly Cys Arg Ala Leu Ser Gly Thr Ser Val Ala 405 410 415 Ser Pro Val Val Ala Gly Ala Val Thr Leu Leu Val Ser Thr Val Gln 420 425 430 Lys Arg Glu Leu Val Asn Pro Ala Ser Met Lys Gln Ala Leu Ile Ala 435 440 445 Ser Ala Arg Arg Leu Pro Gly Val Asn Met Phe Glu Gln Gly His Gly 450 455 460 Lys Leu Asp Leu Leu Arg Ala Tyr Gln Ile Leu Asn Ser Tyr Lys Pro 465 470 475 480 Gln Ala Ser Leu Ser Pro Ser Tyr Ile Asp Leu Thr Glu Cys Pro Tyr 485 490 495 Met Trp Pro Tyr Cys Ser Gln Pro Ile Tyr Tyr Gly Gly Met Pro Thr 500 505 510 Val Val Asn Val Thr Ile Leu Asn Gly Met Gly Val Thr Gly Arg Ile 515 520 525 Val Asp Lys Pro Asp Trp Gln Pro Tyr Leu Pro Gln Asn Gly Asp Asn 530 535 540 Ile Glu Val Ala Phe Ser Tyr Ser Ser Val Leu Trp Pro Trp Ser Gly 545 550 555 560 Tyr Leu Ala Ile Ser Ile Ser Val Thr Lys Lys Ala Ala Ser Trp Glu 565 570 575 Gly Ile Ala Gln Gly His Val Met Ile Thr Val Ala Ser Pro Ala Glu 580 585 590 Thr Glu Ser Lys Asn Gly Ala Glu Gln Thr Ser Thr Val Lys Leu Pro 595 600 605 Ile Lys Val Lys Ile Ile Pro Thr Pro Pro Arg Ser Lys Arg Val Leu 610 615 620 Trp Asp Gln Tyr His Asn Leu Arg Tyr Pro Pro Gly Tyr Phe Pro Arg 625 630 635 640 Asp Asn Leu Arg Met Lys Asn Asp Pro Leu Asp Trp Asn Gly Asp His 645 650 655 Ile His Thr Asn Phe Arg Asp Met Tyr Gln His Leu Arg Ser Met Gly 660 665 670 Tyr Phe Val Glu Val Leu Gly Ala Pro Phe Thr Cys Phe Asp Ala Ser 675 680 685 Gln Tyr Gly Thr Leu Leu Met Val Asp Ser Glu Glu Glu Tyr Phe Pro 690 695 700 Glu Glu Ile Ala Lys Leu Arg Arg Asp Val Asp Asn Gly Leu Ser Leu 705 710 715 720 Val Ile Phe Ser Asp Trp Tyr Asn Thr Ser Val Met Arg Lys Val Lys 725 730 735 Phe Tyr Asp Glu Asn Thr Arg Gln Trp Trp Met Pro Asp Thr Gly Gly 740 745 750 Ala Asn Ile Pro Ala Leu Asn Glu Leu Leu Ser Val Trp Asn Met Gly 755 760 765 Phe Ser Asp Gly Leu Tyr Glu Gly Glu Phe Thr Leu Ala Asn His Asp 770 775 780 Met Tyr Tyr Ala Ser Gly Cys Ser Ile Ala Lys Phe Pro Glu Asp Gly 785 790 795 800 Val Val Ile Thr Gln Thr Phe Lys Asp Gln Gly Leu Glu Val Leu Lys 805 810 815 Gln Glu Thr Ala Val Val Glu Asn Val Pro Ile Leu Gly Leu Tyr Gln 820 825 830 Ile Pro Ala Glu Gly Gly Gly Arg Ile Val Leu Tyr Gly Asp Ser Asn 835 840 845 Cys Leu Asp Asp Ser His Arg Gln Lys Asp Cys Phe Trp Leu Leu Asp 850 855 860 Ala Leu Leu Gln Tyr Thr Ser Tyr Gly Val Thr Pro Pro Ser Leu Ser 865 870 875 880 His Ser Gly Asn Arg Gln Arg Pro Pro Ser Gly Ala Gly Ser Val Thr 885 890 895 Pro Glu Arg Met Glu Gly Asn His Leu His Arg Tyr Ser Lys Val Leu 900 905 910 Glu Ala His Leu Gly Asp Pro Lys Pro Arg Pro Leu Pro Ala Cys Pro 915 920 925 Arg Leu Ser Trp Ala Lys Pro Gln Pro Leu Asn Glu Thr Ala Pro Ser 930 935 940 Asn Leu Trp Lys His Gln Lys Leu Leu Ser Ile Asp Leu Asp Lys Val 945 950 955 960 Val Leu Pro Asn Phe Arg Ser Asn Arg Pro Gln Val Arg Pro Leu Ser 965 970 975 Pro Gly Glu Ser Gly Ala Trp Asp Ile Pro Gly Gly Ile Met Pro Gly 980 985 990 Arg Tyr Asn Gln Glu Val Gly Gln Thr Ile Pro Val Phe Ala Phe Leu 995 1000 1005 Gly Ala Met Val Val Leu Ala Phe Phe Val Val Gln Ile Asn Lys Ala 1010 1015 1020 Lys Ser Arg Pro Lys Arg Arg Lys Pro Arg Val Lys Arg Pro Gln Leu 1025 1030 1035 1040 Met Gln Gln Val His Pro Pro Lys Thr Pro Ser Val 1045 1050 5 4198 DNA Cricetulus griseus CDS (387)..(3545) 5 tgttcgcggc agaggcgccg ttcccccggg cccgccgacc tcgagcctga ggcggacgca 60 ggtcggccct cagagtggtt tcttgggcat ccccactaga tttgggtctg tggtgcaaat 120 ggagtctagg actcagtcga ctctgcccta atgagagaag cccctgtcca agatggagaa 180 gaagcggaga aagaaatgaa agcctctttt tgggccaagc tgtgggtgac catgggactg 240 aggttttctt tacgttggac aagtctgtag gatggctgat cagtaaggtt gcagctttta 300 gccaaaacag aaattcactt ctgatcaagg aagaacctag tgcgatttga atttatgcaa 360 ttttatgacc atattcactt aggacc atg aag ctc atc aac atc tgg ctt ctt 413 Met Lys Leu Ile Asn Ile Trp Leu Leu 1 5 ctg ctg gtg gtt ttg ctc tgt gga aag aag cat ctg ggt gac agg ctg 461 Leu Leu Val Val Leu Leu Cys Gly Lys Lys His Leu Gly Asp Arg Leu 10 15 20 25 ggg aag aaa gcg ttt gaa aag gca tca tgc cct agc tgt tcc cac ctg 509 Gly Lys Lys Ala Phe Glu Lys Ala Ser Cys Pro Ser Cys Ser His Leu 30 35 40 act ttg aag gtg gaa ttc tcc tca act gtg gtg gaa tat gaa tat att 557 Thr Leu Lys Val Glu Phe Ser Ser Thr Val Val Glu Tyr Glu Tyr Ile 45 50 55 gtg gct ttc aac gga tac ttc aca gcc aaa gct aga aac tca ttt att 605 Val Ala Phe Asn Gly Tyr Phe Thr Ala Lys Ala Arg Asn Ser Phe Ile 60 65 70 tca agt gct ctg aaa agc agt gaa gta gac aac tgg aga att ata cct 653 Ser Ser Ala Leu Lys Ser Ser Glu Val Asp Asn Trp Arg Ile Ile Pro 75 80 85 cgg aac aac cca tcc agt gac tac cct agt gat ttt gag gtg att cag 701 Arg Asn Asn Pro Ser Ser Asp Tyr Pro Ser Asp Phe Glu Val Ile Gln 90 95 100 105 ata aaa gag aag cag aag gcc ggg ctg ctc aca ctt gaa gat cat cca 749 Ile Lys Glu Lys Gln Lys Ala Gly Leu Leu Thr Leu Glu Asp His Pro 110 115 120 aac atc aag cgg gtg aca cct caa cgc aaa gtc ttt cgt tcc ttg aag 797 Asn Ile Lys Arg Val Thr Pro Gln Arg Lys Val Phe Arg Ser Leu Lys 125 130 135 ttt gct gaa tct gac ccc att gtg cca tgt aat gaa act cgg tgg agc 845 Phe Ala Glu Ser Asp Pro Ile Val Pro Cys Asn Glu Thr Arg Trp Ser 140 145 150 cag aag tgg cag tca tca cga ccc ctg aga aga gcc agt ctc tcc ctg 893 Gln Lys Trp Gln Ser Ser Arg Pro Leu Arg Arg Ala Ser Leu Ser Leu 155 160 165 ggc tct gga ttc tgg cat gca aca gga aga cat tca agc cgg cga ttg 941 Gly Ser Gly Phe Trp His Ala Thr Gly Arg His Ser Ser Arg Arg Leu 170 175 180 185 ctg aga gcc att cct cga cag gtt gcc cag aca ttg cag gca gat gtg 989 Leu Arg Ala Ile Pro Arg Gln Val Ala Gln Thr Leu Gln Ala Asp Val 190 195 200 ctg tgg cag atg gga tac aca ggt gct aat gtc agg gtt gct gtt ttt 1037 Leu Trp Gln Met Gly Tyr Thr Gly Ala Asn Val Arg Val Ala Val Phe 205 210 215 gat act ggg ctc agt gag aag cat cca cac ttc aag aat gtg aag gag 1085 Asp Thr Gly Leu Ser Glu Lys His Pro His Phe Lys Asn Val Lys Glu 220 225 230 aga acc aac tgg acc aat gag cgg acc ctg gat gat ggg ctg ggc cat 1133 Arg Thr Asn Trp Thr Asn Glu Arg Thr Leu Asp Asp Gly Leu Gly His 235 240 245 ggc aca ttt gtc gca ggt gtg att gcc agc atg agg gag tgc cag gga 1181 Gly Thr Phe Val Ala Gly Val Ile Ala Ser Met Arg Glu Cys Gln Gly 250 255 260 265 ttt gcc cca gat gca gag ctg cac atc ttc cgg gtc ttt acc aac aat 1229 Phe Ala Pro Asp Ala Glu Leu His Ile Phe Arg Val Phe Thr Asn Asn 270 275 280 cag gtg tct tac aca tct tgg ttt ttg gac gct ttc aac tat gcc atc 1277 Gln Val Ser Tyr Thr Ser Trp Phe Leu Asp Ala Phe Asn Tyr Ala Ile 285 290 295 cta aag aag att gat gtt cta aac ctt agc atc ggc ggg cct gac ttc 1325 Leu Lys Lys Ile Asp Val Leu Asn Leu Ser Ile Gly Gly Pro Asp Phe 300 305 310 atg gat cat ccc ttt gtt gac aag gtg tgg gaa tta aca gct aac aat 1373 Met Asp His Pro Phe Val Asp Lys Val Trp Glu Leu Thr Ala Asn Asn 315 320 325 gta atc atg gtt tct gct atc ggc aat gat gga cct ctt tat ggc act 1421 Val Ile Met Val Ser Ala Ile Gly Asn Asp Gly Pro Leu Tyr Gly Thr 330 335 340 345 ctg aat aac cca gct gat cag atg gat gtg att gga gtg ggt ggc att 1469 Leu Asn Asn Pro Ala Asp Gln Met Asp Val Ile Gly Val Gly Gly Ile 350 355 360 gac ttt gaa gat aac atc gcc cgc ttt tct tcc agg gga atg act acc 1517 Asp Phe Glu Asp Asn Ile Ala Arg Phe Ser Ser Arg Gly Met Thr Thr 365 370 375 tgg gaa cta cca gga ggc tat ggt cgc gtg aaa cct gac att gtc acc 1565 Trp Glu Leu Pro Gly Gly Tyr Gly Arg Val Lys Pro Asp Ile Val Thr 380 385 390 tat ggt gcc gga gtg cgg ggt tcc ggt gtg aaa ggg ggc tgc cgg gca 1613 Tyr Gly Ala Gly Val Arg Gly Ser Gly Val Lys Gly Gly Cys Arg Ala 395 400 405 ctc tca ggg acc agt gtc gct tcc cca gtg gtt gct ggg gct gtc acc 1661 Leu Ser Gly Thr Ser Val Ala Ser Pro Val Val Ala Gly Ala Val Thr 410 415 420 425 ttg tta gta agc aca gtg cag aag cgg gag cta gtg aat cct gcc agt 1709 Leu Leu Val Ser Thr Val Gln Lys Arg Glu Leu Val Asn Pro Ala Ser 430 435 440 gtg aag caa gcc ctg att gca tca gcc cgg agg ctt cct ggt gtt aac 1757 Val Lys Gln Ala Leu Ile Ala Ser Ala Arg Arg Leu Pro Gly Val Asn 445 450 455 atg ttc gag caa ggc cat ggc aag ctg gat ctg ctg cga gcc tat cag 1805 Met Phe Glu Gln Gly His Gly Lys Leu Asp Leu Leu Arg Ala Tyr Gln 460 465 470 atc ctc agc agc tac aaa cca cag gcg agc ttg agt cct agc tac atc 1853 Ile Leu Ser Ser Tyr Lys Pro Gln Ala Ser Leu Ser Pro Ser Tyr Ile 475 480 485 gac ctg act gag tgt ccc tac atg tgg cct tac tgt tct cag ccc atc 1901 Asp Leu Thr Glu Cys Pro Tyr Met Trp Pro Tyr Cys Ser Gln Pro Ile 490 495 500 505 tac tat gga gga atg cca aca att gtt aat gtc acc atc ctc aat ggc 1949 Tyr Tyr Gly Gly Met Pro Thr Ile Val Asn Val Thr Ile Leu Asn Gly 510 515 520 atg gga gtc aca gga aga att gtg gat aag cct gag tgg cgg ccc tat 1997 Met Gly Val Thr Gly Arg Ile Val Asp Lys Pro Glu Trp Arg Pro Tyr 525 530 535 tta cca cag aat gga gac aac att gaa gtg gcc ttc tcc tac tcc tca 2045 Leu Pro Gln Asn Gly Asp Asn Ile Glu Val Ala Phe Ser Tyr Ser Ser 540 545 550 gtg tta tgg cct tgg tca ggc tac ctg gcc atc tcc att tct gtg acc 2093 Val Leu Trp Pro Trp Ser Gly Tyr Leu Ala Ile Ser Ile Ser Val Thr 555 560 565 aag aag gca gct tcc tgg gaa ggc att gca cag ggt cac atc atg atc 2141 Lys Lys Ala Ala Ser Trp Glu Gly Ile Ala Gln Gly His Ile Met Ile 570 575 580 585 acg gtg gct tcc cca gca gag acg gaa gca aaa aat ggt gcc gag cat 2189 Thr Val Ala Ser Pro Ala Glu Thr Glu Ala Lys Asn Gly Ala Glu His 590 595 600 act tcc aca gtg aag ctt ccc att aag gtg aag atc att ccc acc cct 2237 Thr Ser Thr Val Lys Leu Pro Ile Lys Val Lys Ile Ile Pro Thr Pro 605 610 615 cct cgg agc aag aga gtc ctc tgg gac cag tat cac aac ctc cgc tac 2285 Pro Arg Ser Lys Arg Val Leu Trp Asp Gln Tyr His Asn Leu Arg Tyr 620 625 630 ccc cca ggc tac ttt ccc agg gac aac ttg cgg atg aag aat gat cct 2333 Pro Pro Gly Tyr Phe Pro Arg Asp Asn Leu Arg Met Lys Asn Asp Pro 635 640 645 tta gac tgg aat ggc gac cat gtc cac acc aat ttc agg gac atg tac 2381 Leu Asp Trp Asn Gly Asp His Val His Thr Asn Phe Arg Asp Met Tyr 650 655 660 665 cag cac ctg cgc agc atg ggc tac ttc gtg gag gtg ctc ggt gcc cca 2429 Gln His Leu Arg Ser Met Gly Tyr Phe Val Glu Val Leu Gly Ala Pro 670 675 680 ttc acg tgc ttt gat gct aca cag tat ggc act ttg ctc atg gtg gat 2477 Phe Thr Cys Phe Asp Ala Thr Gln Tyr Gly Thr Leu Leu Met Val Asp 685 690 695 agt gaa gaa gag tac ttc cca gag gag att gcc aag ctg agg agg gac 2525 Ser Glu Glu Glu Tyr Phe Pro Glu Glu Ile Ala Lys Leu Arg Arg Asp 700 705 710 gtg gac aat ggc ctt tcc ctc gtc atc ttc agt gac tgg tac aac act 2573 Val Asp Asn Gly Leu Ser Leu Val Ile Phe Ser Asp Trp Tyr Asn Thr 715 720 725 tct gtt atg aga aaa gtg aag ttt tac gat gaa aac aca agg cag tgg 2621 Ser Val Met Arg Lys Val Lys Phe Tyr Asp Glu Asn Thr Arg Gln Trp 730 735 740 745 tgg atg cca gat act gga gga gcc aac atc cca gct ctg aac gag ctg 2669 Trp Met Pro Asp Thr Gly Gly Ala Asn Ile Pro Ala Leu Asn Glu Leu 750 755 760 ctg tct gtg tgg aac atg ggg ttc agc gat ggc ctt tat gaa ggg gag 2717 Leu Ser Val Trp Asn Met Gly Phe Ser Asp Gly Leu Tyr Glu Gly Glu 765 770 775 ttt gcc ctg gcg aat cat gac atg tat tat gca tcg gga tgc agc atc 2765 Phe Ala Leu Ala Asn His Asp Met Tyr Tyr Ala Ser Gly Cys Ser Ile 780 785 790 gcc aag ttt cca gaa gat ggt gtt gtg atc aca cag act ttc aag gac 2813 Ala Lys Phe Pro Glu Asp Gly Val Val Ile Thr Gln Thr Phe Lys Asp 795 800 805 caa gga ttg gag gtc tta aaa caa gag aca gca gtt gtt gaa aat gtt 2861 Gln Gly Leu Glu Val Leu Lys Gln Glu Thr Ala Val Val Glu Asn Val 810 815 820 825 ccc att ttg ggg ctt tat cag att cca gct gaa ggt ggg ggc cgg atc 2909 Pro Ile Leu Gly Leu Tyr Gln Ile Pro Ala Glu Gly Gly Gly Arg Ile 830 835 840 gtg ttg tat gga gat tcc aat tgc ttg gat gac agt cac aga cag aag 2957 Val Leu Tyr Gly Asp Ser Asn Cys Leu Asp Asp Ser His Arg Gln Lys 845 850 855 gat tgc ttt tgg ctt ctg gat gca ctc ctt cag tac aca tca tat ggc 3005 Asp Cys Phe Trp Leu Leu Asp Ala Leu Leu Gln Tyr Thr Ser Tyr Gly 860 865 870 gtg aac cct ccc agc ctc agc cat tca ggg aac cgg cag cgc cca ccc 3053 Val Asn Pro Pro Ser Leu Ser His Ser Gly Asn Arg Gln Arg Pro Pro 875 880 885 agt gga gct ggc ttg gcc cct cct gaa agg atg gaa gga aac cac ctt 3101 Ser Gly Ala Gly Leu Ala Pro Pro Glu Arg Met Glu Gly Asn His Leu 890 895 900 905 cat cga tac tcc aag gtt ctt gag gcc cat ctg gga gac cca aaa cct 3149 His Arg Tyr Ser Lys Val Leu Glu Ala His Leu Gly Asp Pro Lys Pro 910 915 920 cgg cct ctt cca gcc tgt cca cac ttg tca tgg gcc aag cca cag cct 3197 Arg Pro Leu Pro Ala Cys Pro His Leu Ser Trp Ala Lys Pro Gln Pro 925 930 935 ttg aat gag act gcg ccc agt aat ctt tgg aaa cat cag aag ctg ctc 3245 Leu Asn Glu Thr Ala Pro Ser Asn Leu Trp Lys His Gln Lys Leu Leu 940 945 950 tcc att gac ctg gac aaa gta gtg tta ccc aac ttt cga tcg aat cgc 3293 Ser Ile Asp Leu Asp Lys Val Val Leu Pro Asn Phe Arg Ser Asn Arg 955 960 965 cct caa gtg aga cct ttg tcc cct gga gaa agt ggt gcc tgg gac att 3341 Pro Gln Val Arg Pro Leu Ser Pro Gly Glu Ser Gly Ala Trp Asp Ile 970 975 980 985 cct gga ggg atc atg cct ggc cgc tac aac caa gag gtg ggc cag acc 3389 Pro Gly Gly Ile Met Pro Gly Arg Tyr Asn Gln Glu Val Gly Gln Thr 990 995 1000 atc cct gtc ttt gcc ttc ctc gga gcc atg gtg gcc ctg gcc ttc ttt 3437 Ile Pro Val Phe Ala Phe Leu Gly Ala Met Val Ala Leu Ala Phe Phe 1005 1010 1015 gtg gta cag atc agc aag gcc aaa agc cgg ccg aag cgg agg agg ccc 3485 Val Val Gln Ile Ser Lys Ala Lys Ser Arg Pro Lys Arg Arg Arg Pro 1020 1025 1030 agg gca aag cgt cca cag ctt aca cag cag acc cac cca cca agg acc 3533 Arg Ala Lys Arg Pro Gln Leu Thr Gln Gln Thr His Pro Pro Arg Thr 1035 1040 1045 ccg tca gtg tga tcatcacagt ggccagccac agaagccaac aagccttgga 3585 Pro Ser Val 1050 ccactctgat ggccacacag ggcatcagaa gagcatcctg ggaggtgcct atttccaagg 3645 gaccccatct ccagcttgtg gctgggttag tgtgttctcc ccaggcatct ctgagttaca 3705 tcctgaagta cctcactgtg ctgggctctt gacaggaggt gctcagtagc tcagcctcca 3765 gtggtgtcag caggcccagt gacagtgcac caaagacaca gagcctggaa gggctgtcgg 3825 gacacacttt ctacataaag cttacaatcc tgaccaagcg aagaaatgct tgttacaggc 3885 tattttctat atttattgtg gggagagtca ctttaaagac ttgtactgtt tggaagcaaa 3945 gctgttgtgt ttgtcagttg agtgcagttt tctgcagtga catcataagg agtcagatcc 4005 catgaccttt ttgatgagag gacagactga actgaagggc atgtgcacag atctgggaaa 4065 tgcaagcctt cgctttattt ttataagtat caactgccat catgttttgt aatttggggt 4125 cttgatttca ccattgttgg tgaaagaaat tttcaataaa tatgcataac cttaaaaaaa 4185 aaaaaaaaaa aaa 4198 6 1052 PRT Cricetulus griseus 6 Met Lys Leu Ile Asn Ile Trp Leu Leu Leu Leu Val Val Leu Leu Cys 1 5 10 15 Gly Lys Lys His Leu Gly Asp Arg Leu Gly Lys Lys Ala Phe Glu Lys 20 25 30 Ala Ser Cys Pro Ser Cys Ser His Leu Thr Leu Lys Val Glu Phe Ser 35 40 45 Ser Thr Val Val Glu Tyr Glu Tyr Ile Val Ala Phe Asn Gly Tyr Phe 50 55 60 Thr Ala Lys Ala Arg Asn Ser Phe Ile Ser Ser Ala Leu Lys Ser Ser 65 70 75 80 Glu Val Asp Asn Trp Arg Ile Ile Pro Arg Asn Asn Pro Ser Ser Asp 85 90 95 Tyr Pro Ser Asp Phe Glu Val Ile Gln Ile Lys Glu Lys Gln Lys Ala 100 105 110 Gly Leu Leu Thr Leu Glu Asp His Pro Asn Ile Lys Arg Val Thr Pro 115 120 125 Gln Arg Lys Val Phe Arg Ser Leu Lys Phe Ala Glu Ser Asp Pro Ile 130 135 140 Val Pro Cys Asn Glu Thr Arg Trp Ser Gln Lys Trp Gln Ser Ser Arg 145 150 155 160 Pro Leu Arg Arg Ala Ser Leu Ser Leu Gly Ser Gly Phe Trp His Ala 165 170 175 Thr Gly Arg His Ser Ser Arg Arg Leu Leu Arg Ala Ile Pro Arg Gln 180 185 190 Val Ala Gln Thr Leu Gln Ala Asp Val Leu Trp Gln Met Gly Tyr Thr 195 200 205 Gly Ala Asn Val Arg Val Ala Val Phe Asp Thr Gly Leu Ser Glu Lys 210 215 220 His Pro His Phe Lys Asn Val Lys Glu Arg Thr Asn Trp Thr Asn Glu 225 230 235 240 Arg Thr Leu Asp Asp Gly Leu Gly His Gly Thr Phe Val Ala Gly Val 245 250 255 Ile Ala Ser Met Arg Glu Cys Gln Gly Phe Ala Pro Asp Ala Glu Leu 260 265 270 His Ile Phe Arg Val Phe Thr Asn Asn Gln Val Ser Tyr Thr Ser Trp 275 280 285 Phe Leu Asp Ala Phe Asn Tyr Ala Ile Leu Lys Lys Ile Asp Val Leu 290 295 300 Asn Leu Ser Ile Gly Gly Pro Asp Phe Met Asp His Pro Phe Val Asp 305 310 315 320 Lys Val Trp Glu Leu Thr Ala Asn Asn Val Ile Met Val Ser Ala Ile 325 330 335 Gly Asn Asp Gly Pro Leu Tyr Gly Thr Leu Asn Asn Pro Ala Asp Gln 340 345 350 Met Asp Val Ile Gly Val Gly Gly Ile Asp Phe Glu Asp Asn Ile Ala 355 360 365 Arg Phe Ser Ser Arg Gly Met Thr Thr Trp Glu Leu Pro Gly Gly Tyr 370 375 380 Gly Arg Val Lys Pro Asp Ile Val Thr Tyr Gly Ala Gly Val Arg Gly 385 390 395 400 Ser Gly Val Lys Gly Gly Cys Arg Ala Leu Ser Gly Thr Ser Val Ala 405 410 415 Ser Pro Val Val Ala Gly Ala Val Thr Leu Leu Val Ser Thr Val Gln 420 425 430 Lys Arg Glu Leu Val Asn Pro Ala Ser Val Lys Gln Ala Leu Ile Ala 435 440 445 Ser Ala Arg Arg Leu Pro Gly Val Asn Met Phe Glu Gln Gly His Gly 450 455 460 Lys Leu Asp Leu Leu Arg Ala Tyr Gln Ile Leu Ser Ser Tyr Lys Pro 465 470 475 480 Gln Ala Ser Leu Ser Pro Ser Tyr Ile Asp Leu Thr Glu Cys Pro Tyr 485 490 495 Met Trp Pro Tyr Cys Ser Gln Pro Ile Tyr Tyr Gly Gly Met Pro Thr 500 505 510 Ile Val Asn Val Thr Ile Leu Asn Gly Met Gly Val Thr Gly Arg Ile 515 520 525 Val Asp Lys Pro Glu Trp Arg Pro Tyr Leu Pro Gln Asn Gly Asp Asn 530 535 540 Ile Glu Val Ala Phe Ser Tyr Ser Ser Val Leu Trp Pro Trp Ser Gly 545 550 555 560 Tyr Leu Ala Ile Ser Ile Ser Val Thr Lys Lys Ala Ala Ser Trp Glu 565 570 575 Gly Ile Ala Gln Gly His Ile Met Ile Thr Val Ala Ser Pro Ala Glu 580 585 590 Thr Glu Ala Lys Asn Gly Ala Glu His Thr Ser Thr Val Lys Leu Pro 595 600 605 Ile Lys Val Lys Ile Ile Pro Thr Pro Pro Arg Ser Lys Arg Val Leu 610 615 620 Trp Asp Gln Tyr His Asn Leu Arg Tyr Pro Pro Gly Tyr Phe Pro Arg 625 630 635 640 Asp Asn Leu Arg Met Lys Asn Asp Pro Leu Asp Trp Asn Gly Asp His 645 650 655 Val His Thr Asn Phe Arg Asp Met Tyr Gln His Leu Arg Ser Met Gly 660 665 670 Tyr Phe Val Glu Val Leu Gly Ala Pro Phe Thr Cys Phe Asp Ala Thr 675 680 685 Gln Tyr Gly Thr Leu Leu Met Val Asp Ser Glu Glu Glu Tyr Phe Pro 690 695 700 Glu Glu Ile Ala Lys Leu Arg Arg Asp Val Asp Asn Gly Leu Ser Leu 705 710 715 720 Val Ile Phe Ser Asp Trp Tyr Asn Thr Ser Val Met Arg Lys Val Lys 725 730 735 Phe Tyr Asp Glu Asn Thr Arg Gln Trp Trp Met Pro Asp Thr Gly Gly 740 745 750 Ala Asn Ile Pro Ala Leu Asn Glu Leu Leu Ser Val Trp Asn Met Gly 755 760 765 Phe Ser Asp Gly Leu Tyr Glu Gly Glu Phe Ala Leu Ala Asn His Asp 770 775 780 Met Tyr Tyr Ala Ser Gly Cys Ser Ile Ala Lys Phe Pro Glu Asp Gly 785 790 795 800 Val Val Ile Thr Gln Thr Phe Lys Asp Gln Gly Leu Glu Val Leu Lys 805 810 815 Gln Glu Thr Ala Val Val Glu Asn Val Pro Ile Leu Gly Leu Tyr Gln 820 825 830 Ile Pro Ala Glu Gly Gly Gly Arg Ile Val Leu Tyr Gly Asp Ser Asn 835 840 845 Cys Leu Asp Asp Ser His Arg Gln Lys Asp Cys Phe Trp Leu Leu Asp 850 855 860 Ala Leu Leu Gln Tyr Thr Ser Tyr Gly Val Asn Pro Pro Ser Leu Ser 865 870 875 880 His Ser Gly Asn Arg Gln Arg Pro Pro Ser Gly Ala Gly Leu Ala Pro 885 890 895 Pro Glu Arg Met Glu Gly Asn His Leu His Arg Tyr Ser Lys Val Leu 900 905 910 Glu Ala His Leu Gly Asp Pro Lys Pro Arg Pro Leu Pro Ala Cys Pro 915 920 925 His Leu Ser Trp Ala Lys Pro Gln Pro Leu Asn Glu Thr Ala Pro Ser 930 935 940 Asn Leu Trp Lys His Gln Lys Leu Leu Ser Ile Asp Leu Asp Lys Val 945 950 955 960 Val Leu Pro Asn Phe Arg Ser Asn Arg Pro Gln Val Arg Pro Leu Ser 965 970 975 Pro Gly Glu Ser Gly Ala Trp Asp Ile Pro Gly Gly Ile Met Pro Gly 980 985 990 Arg Tyr Asn Gln Glu Val Gly Gln Thr Ile Pro Val Phe Ala Phe Leu 995 1000 1005 Gly Ala Met Val Ala Leu Ala Phe Phe Val Val Gln Ile Ser Lys Ala 1010 1015 1020 Lys Ser Arg Pro Lys Arg Arg Arg Pro Arg Ala Lys Arg Pro Gln Leu 1025 1030 1035 1040 Thr Gln Gln Thr His Pro Pro Arg Thr Pro Ser Val 1045 1050 

1. An isolated human site-1 protease promoter region comprising a sequence selected from: (a) the nucleotide sequence set forth as SEQ ID NO: 2, or a fragment thereof exhibiting site-1 protease promoter activity; (b) the complementary strand of (a); and (c) nucleotide sequences capable of hybridizing, under stringent hybridization conditions, to a nucleotide sequence as defined in (a) or (b).
 2. A recombinant construct comprising the human site-1 protease promoter region according to claim
 1. 3. The recombinant construct according to claim 2 wherein the human site-1 protease promoter region is operably linked to a gene encoding a detectable product.
 4. The recombinant construct according to claim 3 wherein said gene encoding a detectable product is a human site-1 protease gene.
 5. The recombinant construct according to claim 2 further comprising a reporter gene.
 6. A vector comprising the recombinant construct according to any one of claims 2 to
 5. 7. A host cell stably transformed with the recombinant construct according to any one of claims 2 to
 5. 8. A host cell stably transformed with the vector according to claim
 6. 9. A method for identification of an agent capable of decreasing or inhibiting site-1 protease promoter activity, said method comprising the steps (i) contacting a candidate agent with the human site-1 protease promoter; and (ii) determining whether said candidate agent decreases expression of the site-1 protease gene, such decrease being indicative for an agent capable of decreasing or inhibiting site-1 protease promoter activity.
 10. A method for identification of an agent useful for the treatment of a medical condition related to obesity, said method comprising the steps (i) contacting a candidate agent with the human site-1 protease promoter; and (ii) determining whether said candidate agent decreases expression of the site-1 protease gene, such decrease being indicative for an agent useful for the treatment of a medical condition related to obesity.
 11. A method for identification of an agent capable of decreasing or inhibiting site-1 protease promoter activity, said method comprising assaying reporter gene expression in a cell according to claim 7 or 8 in the presence and absence of a candidate agent, wherein a decrease or inhibition of test level of expression as compared to control level of expression is indicative of an agent capable of decreasing or inhibiting site-1 protease promoter activity.
 12. A method for identification of an agent useful for the treatment of medical conditions related to obesity, said method comprising assaying reporter gene expression in a cell according to claim 7 or 8 in the presence and absence of a candidate agent, wherein a decrease or inhibition of test level of expression as compared to control level of expression is indicative of an agent useful for the treatment of medical conditions related to obesity.
 13. Use of a compound identified by the method according to any one of claims 9 to 12 in the manufacture of a medicament for the treatment of medical conditions related to obesity.
 14. A method for the treatment of medical conditions related to obesity, comprising administering to a patient in need thereof a therapeutically effective amount of an agent identified by the method according to any one of claims 9 to
 12. 